Deep dive

Matinas BioPharma advances the promise of heart-healthy omega-3 fatty acids

The New Jersey-based company's lead product candidate, MAT9001 is for the treatment of...

4 days, 4 hours ago
Deep dive

Zynerba's CBD skin gel Zygel offers a goldmine of therapies for Fragile X...

All eyes are on Zynerba's meeting with the FDA in the fourth quarter of 2020 to discuss pivotal...

4 days, 17 hours ago
Deep dive

Milestone Scientific eyeing upswing in dental sales as world unlocks, while...

The company is advancing computer-controlled drug delivery systems that offer significant...

6 days, 4 hours ago

Bioasis on a roll after Chiesi validates the power of its technology to...

Bioasis will get an upfront payment of $3 million from Chiesi and may also be eligible to...

6 days, 19 hours ago

Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

5 hours, 42 minutes ago

Join Proactive

Get ahead of the curve

First with the equities news

Get our market previews and stories before the main networks.

Widest with the analysis

Not just the FTSE. Read about
opportunities from the whole
equities market.

Closest to the source

Hear directors at first-hand
or meet them in person at our events.

In at the start

Watch IPOs and access on the same terms as the institutions.